STOCK TITAN
  1. Home
  2. Sec-filings
  3. LMED
  4. [8-K] LataMed AI Corp. Reports Material Event

LataMed AI Corp. (OTC: LMED) completes 5-for-1 forward split

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

LataMed AI Corp. is implementing a 5-for-1 forward stock split that became effective at the opening of trading after its corporate action appeared on the FINRA Daily List dated July 14, 2026. Common stock now trades under temporary symbol LMEDD with a “D” suffix expected for approximately twenty business days before reverting to LMED.

The split is tied to a mandatory share exchange and a new CUSIP number 21116R404, with the prior CUSIP 21116R305 suspended upon effectiveness. Shares held in brokerage or book-entry form are expected to adjust automatically, while holders of physical certificates will receive the appropriate number of post-split shares when they submit certificates through the transfer agent.

The company continues to focus on expanding its telemedicine platform and commercializing its CardioAI, PulmoAI, and NeuroAI healthcare AI solutions, initially targeting Latin American markets.

Positive

  • None.

Negative

  • None.
Forward stock split ratio 5-for-1 Forward stock split effective at the opening of trading following FINRA Daily List dated July 14, 2026
Temporary ticker duration approximately twenty (20) business days Expected period the temporary trading symbol LMEDD with a “D” suffix remains before reverting to LMED
New CUSIP 21116R404 CUSIP assigned to post-split common shares under the mandatory share exchange
Prior CUSIP suspended 21116R305 CUSIP suspended effective upon market effectiveness of the forward stock split
forward stock split financial
"previously announced 5-for-1 forward stock split has become effective"
A forward stock split is when a company increases the number of its shares by dividing each existing share into smaller parts. This makes the stock price lower and more affordable for investors, similar to splitting a pizza into more slices so everyone can get a smaller piece. It doesn't change the company's total value, just how it's divided among shareholders.
FINRA Daily List regulatory
"following publication of the corporate action on the FINRA Daily List dated July 14, 2026"
mandatory share exchange financial
"implemented in conjunction with the Company's mandatory share exchange and new CUSIP number"
CUSIP financial
"new CUSIP number, 21116R404. In connection with the corporate action, the Company's prior CUSIP number"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
telemedicine platform medical
"expanding our telemedicine platform and pursuing commercialization opportunities"
A telemedicine platform is a digital service that lets patients and healthcare providers consult, diagnose, and monitor health remotely through video calls, messaging, remote monitoring devices, and electronic records. Investors care because these platforms can scale patient visits, lower costs, create recurring revenue from subscriptions or pay-per-visit models, and face regulatory and data-security risks that affect growth and valuation. Think of it as a virtual clinic or storefront for medical care.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What stock split did LataMed AI Corp. (LMED) implement?
LataMed AI Corp. implemented a 5-for-1 forward stock split, which became effective at the opening of trading after the corporate action appeared on the FINRA Daily List dated July 14, 2026.

What is the temporary trading symbol for LataMed AI (LMED) after the split?
Following the split, LataMed AI’s common stock trades under temporary symbol LMEDD. The “D” suffix is a standard FINRA identifier and is expected to remain for approximately twenty business days before reverting to LMED.

How does the LataMed AI (LMED) stock split affect shareholders with brokerage accounts?
Shareholders holding LataMed AI shares in brokerage or book-entry form generally do not need to take action. Brokerage firms, custodians, and other market participants are expected to process the stock split and share exchange automatically through normal settlement processes.

What should LataMed AI (LMED) shareholders with physical certificates do after the split?
Holders of physical certificates are not required to immediately surrender them. When certificates are later presented to the transfer agent for transfer, sale, or exchange, they will be processed under mandatory exchange procedures into the appropriate number of post-split shares.

What is the new CUSIP for LataMed AI (LMED) common stock post-split?
Post-split LataMed AI common shares carry new CUSIP 21116R404. The prior CUSIP 21116R305 is being suspended effective upon market effectiveness of the forward stock split and related mandatory share exchange.

What markets and technologies is LataMed AI Corp. (LMED) focusing on?
LataMed AI is a development-stage digital health and AI company building telehealth, coordination, analytics, and AI healthcare solutions, initially focused on Latin America and targeting areas such as CardioAI, PulmoAI, and NeuroAI platforms.

EXHIBIT 99.1 

 

LataMed AI Corp. Announces Effectiveness of 5-for-1 Forward Stock Split

 

Caracas, Venezuela – July 15, 2026 – LataMed AI Corp. (OTC: LMED) (the “Company”) today announced that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication of the corporate action on the FINRA Daily List dated July 14, 2026.

 

In connection with the forward stock split, the Company's common stock will begin trading today under the temporary trading symbol LMEDD. The temporary "D" designation is a standard FINRA identifier used in connection with certain corporate actions and is expected to remain in place for approximately twenty (20) business days, after which the trading symbol is expected to revert to LMED.

 

The forward stock split has also been implemented in conjunction with the Company's mandatory share exchange and new CUSIP number, 21116R404. In connection with the corporate action, the Company's prior CUSIP number, 21116R305, is being suspended effective upon market effectiveness of the forward stock split.

 

The Company wishes to remind shareholders that those holding shares through brokerage accounts or in electronic book-entry form generally are not required to take any action. Brokerage firms, custodians, and other market participants are expected to process the corporate action automatically through the normal securities settlement process.

 

Shareholders holding physical stock certificates are not required to immediately surrender their certificates. However, when physical certificates are presented to the Company's transfer agent for transfer, sale, or exchange, they will be processed in accordance with the mandatory exchange procedures then in effect and exchanged for the appropriate number of post-split shares under the new CUSIP.

 

Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms.”

 

The Company encourages shareholders with questions regarding the exchange process to contact their brokerage firm or the Company's transfer agent for additional information.

 

For additional information, please visit https://latamed.ai, follow the Company's official social media channels, or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

 

About LataMed AI Corp.

 

LataMed AI Corp. (OTC: LMED) is a development-stage digital health and artificial intelligence technology company focused on building telehealth infrastructure, healthcare coordination tools, analytics capabilities, and AI-enabled healthcare solutions for emerging markets. The Company's strategy is centered on developing technology platforms designed to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven healthcare operations, with an initial regional focus on Latin America.

 

 
1

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the Company's business strategy, corporate actions, forward stock split implementation, mandatory share exchange procedures, capital structure initiatives, healthcare technology initiatives, commercialization initiatives, operational execution, strategic commercial relationships, market opportunities, regional expansion plans, and future operations.

 

These statements are based on current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 

Actual results may differ materially due to various factors, including, but not limited to, the Company's ability to successfully implement its business plan; the availability of financing; the Company's ability to obtain required regulatory authorizations; operational execution risks; technology deployment risks; risks associated with operations in emerging markets; the completion and processing of the forward stock split and mandatory share exchange; the Company's ability to pursue commercialization opportunities for its healthcare technology platforms; and general economic and market conditions.

 

The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

 

Disclaimer

 

This press release is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company. Any investment decision should be made solely on the basis of information contained in the Company's filings with the U.S. Securities and Exchange Commission and other publicly available documents.

 

The Company's securities involve a high degree of risk. Prospective investors are urged to carefully review all risk factors and disclosures contained in the Company's SEC filings before making any investment decision.

 

No representation or warranty, express or implied, is made as to the accuracy or completeness of the information contained herein.

 

Investor Relations Contact

 

LataMed AI Corp.

ir@latamed.ai

+1 (787) 476-2350

https://latamed.ai

 

 
2

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Press Releases

Other Documents